The main objective of this study is to confirm long-term safety, performance, and clinical benefits of the Vivacit-E Vitamin E HXLPE Elevated Liners when used in primary total hip arthroplasty.

Inclusion Criteria:

• Patient was 18 years of age or older and skeletally mature at the time of surgery
• Patient qualified for and underwent surgical procedure with a Vivacit-E Vitamin E HXLPE Elevated Liner to treat one of the following indications in primary THA:
• Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
• Protrusio acetabuli
• Traumatic arthritis
• Slipped capital epiphysis
• Fused hip
• Fracture of the pelvis
• Diastrophic variant
• Patient underwent surgical procedure 10 years (+ no maximum/- 182 days) prior to date of study consent
• Patient is will and able to sign IRB approved Informed Consent Form or provide verbal consent

Exclusion Criteria:

• Off label use or not according to the approved IFU at the time of surgery

• Patient presented with any of the following at the time of the surgical procedure:

• Osteoradionecrosis

• Neuromuscular compromise, vascular deficiency or other conditions in the affected limb that may lead to inadequate skeletal fixation

• Systemic or local infection

• Revision procedure where other treatment or devices have failed*

• Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent

• Uncooperative patient or patient with neurologic disorders who is incapable or unwilling to follow directions

  • For the purpose of this clinical study; a revision procedure refers to a procedure in which the prior procedure on the ipsilateral hip utilized a similar approach (i.e., primary total hip arthoplasty)

The study population should consist of a maximum of 52 subjects implanted 10 years ago with the Vivacit-E Vitamin E HXLPE Elevated Liner in total hip arthroplasty, according to the approved indications.